Skip to main content

Table 1 Demographic data

From: The effect of propofol and sevoflurane on cancer cell, natural killer cell, and cytotoxic T lymphocyte function in patients undergoing breast cancer surgery: an in vitro analysis

  Propofol group
(n = 23)
Sevoflurane group
(n = 21)
P
Age (years) 52 (49–58) 47 (45–53) 0.072
Height (cm) 157.7 ± 5.9 158.8 ± 4.7 0.511
Weight (kg) 57.8 ± 6.8 58.7 ± 10.6 0.738
Stage    0.903
 I 4 (17%) 5 (24%)  
 II 16 (70%) 13 (62%)  
 III 3 (13%) 3 (14%)  
 IV 0 (0%) 0 (0%)  
Operation    0.887
 Partial mastectomy 4 (17%) 5 (24%)  
 Breast conserving surgery 17 (74%) 14 (67%)  
 Modified radical mastectomy 2 (9%) 2 (9%)  
Anaesthetics
 Minetsevoflurane (Vol%) 0 1.5 (1.0–1.5) 0.000
 Maxetsevoflurane (Vol%) 0 2.0 (2.0–2.2) 0.000
 Min-Ce of propofol (μg/ml) 2.7 (2.0–3.0) 0 0.000
 Max-Ce of propofol (μg/ml) 3.5 (3.0–4.0) 0 0.000
Opioids
 Intraoperative remifentanil (μg) 1454 ± 288 1521 ± 512 0.602
 Postoperative ketorolac (mg) 0 (0–12) 0 (0–19) 0.905
Duration of anaesthesia (min) 132 (109–155) 128 (115–196) 0.391
Duration of operation (min) 97 ± 33 114 ± 44 0.168
  1. Data are expressed as medians (25–75%), means ± standard deviation, or numbers of patients
  2. Abbreviations: Min et sevoflurane minimal end-expiratory concentration of sevoflurane, Max et sevoflurane maximal end-expiratory concentration of sevoflurane, Min-C e of propofol minimal effect-site target concentration of propofol, Max-C e of propofol maximal effect-site target concentration of propofol